Peter Mollee

5PUBLICATIONS
30CO-AUTHORS
Molecular targetsAutoimmunityHaematological tumoursRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Sep 16, 2026
Toxicity-Related Treatment Cessation in Newly Diagnosed Multiple Myeloma-Risk Factors and Survival: An Analysis From the APAC and ANZ Myeloma and Related Diseases Registry.

|Feb 22, 2026
An Australian Amyloidosis Network analysis of Australian patients with immunoglobulin light chain amyloidosis treated with bortezomib-based chemotherapy.

Anthea Gibbons, Lipi Chakravorty, Hasib Sidiqi

|Jan 08, 2026
Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

Shirlene Sim, Georgia McCaughan, Andrew Zannettino

|May 13, 2024
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16.

Peter Mollee, John Reynolds, Wojt Janowski

Pageof 1

Frequent Collaborators

2 joint publications

Hang Quach

2 joint publications

Phoebe Joy Ho

1 joint publications

John Reynolds

1 joint publications

Kerry Taylor